Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (PRO-Go)

A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets

This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.

Study Overview

• Status: Completed
• Conditions: Idiopathic Parkinson Disease
• Intervention / Treatment: Drug: XADAGO (safinamide)

Detailed Description

This Phase IV, multicenter, prospective, observational study to evaluate clinician-reported outcomes and patient-reported outcomes related to motor and non-motor symptoms, health status, quality of life and treatment satisfaction in PD patients who have been newly prescribed XADAGO according to Package Insert indication.

This study also will gather "real world" data from a PD population in the US regarding their overall experience and degree of satisfaction with the use of XADAGO as an add-on treatment to their L-dopa regimen. Treatment experience will be captured using patient self-rating assessments as well as clinician ratings on assessments.

• Study Type: Observational
• Enrollment (Actual): 164

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Homewood, Alabama, United States, 35244
      • Alabama Neurology Associates
  • California
    • Bakersfield, California, United States, 93312
      • Movement Disorders Neurology, Inc.
    • Laguna Hills, California, United States, 92653
      • B.E.S.T. Center of Orange County
    • Los Gatos, California, United States, 95032
      • Valley Parkinson Clinic
    • Sacramento, California, United States, 95817
      • UC Davis Medical Center
  • Connecticut
    • Vernon, Connecticut, United States, 06066
      • Hartford Healthcare
  • District of Columbia
    • Washington, District of Columbia, United States, 20007
      • Georgetown University Hospital
  • Florida
    • Boca Raton, Florida, United States, 33486
      • Parkinson's Disease and Movement Disorders Center of Boca Raton
    • Naples, Florida, United States, 34108
      • Neuron Research
    • Port Charlotte, Florida, United States, 33980
      • Parkinson's Disease Treatment Center of SW Florida
    • Sarasota, Florida, United States, 34239
      • Sarasota Memorial Hospital Clinical Research Cener
  • Illinois
    • Winfield, Illinois, United States, 60190
      • Central DuPage Hospital
  • Kansas
    • Kansas City, Kansas, United States, 66160
      • University of Kansas Medical Center
  • Kentucky
    • Richmond, Kentucky, United States, 40475
      • Baptist Health System
  • Louisiana
    • Gray, Louisiana, United States, 70359
      • Southeast Neuroscience Center, LLC
  • Missouri
    • Springfield, Missouri, United States, 65807
      • Lester and Cox Medical Center
  • New York
    • Lake Success, New York, United States, 11042
      • Neurological Associates of Long Island, PC
    • Mineola, New York, United States, 11501
      • NYU Winthrop Hospital
  • North Carolina
    • Hickory, North Carolina, United States, 28602
      • FryeCare Neurology
  • Ohio
    • Centerville, Ohio, United States, 45459
      • Dayton center for neurological disorders
  • Oklahoma
    • Tulsa, Oklahoma, United States, 74137
      • The Movement Disorder Clinic of Oklahoma
  • Pennsylvania
    • Lititz, Pennsylvania, United States, 17543
      • Neurology and Stroke Associates
  • South Carolina
    • Greenville, South Carolina, United States, 29615
      • Prisma Health
  • Texas
    • Lubbock, Texas, United States, 79410
      • Covenant Medical Group
    • Sherman, Texas, United States, 75092
      • Texas Institute for Neurological Disorders
    • Sugar Land, Texas, United States, 77479
      • Houston Methodist - Sugar Land
    • Temple, Texas, United States, 76508
      • Baylor Scott and White Health
  • Virginia
    • Alexandria, Virginia, United States, 22311
      • Inova Medical Group- Neurology I
    • Norfolk, Virginia, United States, 23502
      • Meridian Clinical Research, LLC
  • Washington
    • Tacoma, Washington, United States, 98409
      • Puget Sound Neurology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Parkinson's Disease patients who have been newly prescribed XADAGO

Description

Inclusion Criteria:

1. Patient (and Care Partner, if required per Inclusion Criterion 6) is able to understand and provide signed informed consent and HIPAA authorization in English.
2. Patient with diagnosis of idiopathic PD (all stages).
3. Independent of the study, clinician's and patient's choice of treatment is XADAGO in accordance with the Package Insert indication.
4. Patient is willing and able to participate in the study and complete study-related assessments for 2 months and, patients can continue for an optional 4-month study extension.
5. Patient has access to an electronic device for the interim completion of PROs.
6. Patient has an available Care Partner who is able and willing to assist with clinic attendance and completion of study assessments (e.g., PROs, health outcomes, etc.), if in the PI's opinion, assistance is needed to comply with all study visits and procedures.

Exclusion Criteria:

1. Any of the warnings, precautions, or contraindications listed in the XADAGO Package Insert that in the opinion of the PI would prevent appropriate treatment with XADAGO or impair study participation (e.g., pregnancy, lactation, severe hepatic impairment, etc.).
2. Participation in any other clinical trial of an investigational drug or device within 4 weeks prior to the Baseline Visit or at any time during the study.
3. Patient is currently receiving chemotherapy or radiation for any form of cancer (if history of cancer, must be in clinical remission at study entry) or currently receiving immunotherapy.
4. Patients with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate or severe dementia as determined by the clinician (not to include mild cognitive impairment [MCI]); major psychiatric illness (specifically diagnosis of schizophrenia, bipolar disorder or a history of attempted suicide); and/or severe and progressive medical illness (including terminal cancer, end-stage renal disease +/- undergoing dialysis).
5. Severe or unpredictable dyskinesia at the time of the Baseline Visit.
6. Previous participation in this study; a patient may not re-enroll after prior discontinuation or completion

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Parkinson's Disease Patients; PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert	Drug: XADAGO (safinamide); XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.; Other Names: XADAGO; safinamide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Movement Disorders Society -Unified Parkinson's Disease Rating Scale (MDS-UPDRS)	MDS-UPDRS: 4-part assessment of the multiple clinical disabilities of Parkinson's Disease. Part I (13 items; Score 0-52) examines non-motor experiences, Part II (13 items; Score 0-52) examines motor experiences, Part III (33 items; Score 0-132) examines the cardinal motor disabilities and Part IV (6 items; Score 0-24) examines motor complications. Each Part has 0-4 ratings, where 0 (no problems) to 4 (severe problems) and scores for each part are summed to calculate the total score which ranges from 0-260. Higher scores represent worse outcomes for each part and total score.	Baseline to Study Day 60
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Scores	PDQ-39 is a patient-reported outcome designed to address aspects of functioning and well-being for those affected by PD. Each of the 39 items is rated using a 5 point Likert scale with 0 for never having difficulties/problems and 4 for always having difficulties/problems. The sum score of the 39 items will be calculated and used for analysis, with scores ranging from 0-156. Higher scores indicate worse outcomes.	Baseline to Study Day 60
Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score.	MoCA is a 30-point, 1-page test designed to assess several cognitive domains, including visuospatial abilities (5 points), naming (3 points), attention (6 points), language (3 points), abstraction (2 points), delayed recall (5 points), and orientation to time and place (6 points). The total score ranges from 0 to 30, with higher scores indicating better performances.	Baseline to Study Day 60
Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores	TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions will be calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.	Study Day 60
Clinical Global Impression of Change (CGI-C)	CGI-C is a 7-point scale depicting a Principal Investigator or certified Health Care Professional designee rating of the patient's overall improvement using a range of responses from a minimum of 1 (very much improved) to a maximum of 7 (very much worse).	Study Day 60
Patient Global Impression of Change (PGI-C)	PGI-C is a 7-point scale depicting a patient's rating of overall improvement using a range of responses from 1 (very much improved) to 7 (very much worse).	Study Day 60

Collaborators and Investigators

• Sponsor: Supernus Pharmaceuticals, Inc.
• Investigators: Study Director: Najeebah Abdul-Musawir, MD,MBA, Supernus Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): November 30, 2017
• Primary Completion (Actual): December 23, 2019
• Study Completion (Actual): January 10, 2020

Study Registration Dates

• First Submitted: May 1, 2019
• First Submitted That Met QC Criteria: May 8, 2019
• First Posted (Actual): May 10, 2019

Study Record Updates

• Last Update Posted (Actual): June 7, 2023
• Last Update Submitted That Met QC Criteria: June 5, 2023
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: Safinamide; levodopa; Parkinson's disease; PD; motor symptoms; non-motor symptoms; Xadago; MAO-B inhibitor; off
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: USWM-SA1-4001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No